MD3790548T2 - Metode de îmbunătățire a biodisponibilității și expunerii activatorului de canale de potasiu voltaj-dependente - Google Patents
Metode de îmbunătățire a biodisponibilității și expunerii activatorului de canale de potasiu voltaj-dependenteInfo
- Publication number
- MD3790548T2 MD3790548T2 MDE20210233T MDE20210233T MD3790548T2 MD 3790548 T2 MD3790548 T2 MD 3790548T2 MD E20210233 T MDE20210233 T MD E20210233T MD E20210233 T MDE20210233 T MD E20210233T MD 3790548 T2 MD3790548 T2 MD 3790548T2
- Authority
- MD
- Moldova
- Prior art keywords
- methods
- voltage
- potassium channel
- gated potassium
- bioavailability
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 title abstract 2
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000004036 potassium channel stimulating agent Substances 0.000 title 1
- 229940126062 Compound A Drugs 0.000 abstract 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 2
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
În anumite exemple de realizare, prezenta dezvăluire se referă la metode şi utilizări pentru tratarea tulburărilor convulsive la un om, în care metodele şi utilizările cuprind administrarea orală a unei cantităţi eficiente terapeutic din modulatorul alosteric al canalului de potasiu dependent de tensiune, N-[4-(6)-fluor-3,4-dihidro-1 H-izochinolin-2-il)-2,6-dimetilfenil]-3,3-dimetilbutanamidă (Compusul A), la om care are nevoie de aceasta, de exemplu, în condiţii de hrănire. Prezenta dezvăluire este în continuare direcţionată către diferite metode îmbunătăţite de terapie şi administrare a Compusului A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670253P | 2018-05-11 | 2018-05-11 | |
| PCT/US2019/031872 WO2019217924A1 (en) | 2018-05-11 | 2019-05-10 | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3790548T2 true MD3790548T2 (ro) | 2024-02-29 |
Family
ID=66669101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20210233T MD3790548T2 (ro) | 2018-05-11 | 2019-05-10 | Metode de îmbunătățire a biodisponibilității și expunerii activatorului de canale de potasiu voltaj-dependente |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11135214B2 (ro) |
| EP (2) | EP4279133A3 (ro) |
| JP (1) | JP2021523130A (ro) |
| KR (1) | KR20210020892A (ro) |
| CN (1) | CN112384216A (ro) |
| AU (1) | AU2019265002A1 (ro) |
| BR (1) | BR112020022713A2 (ro) |
| CA (1) | CA3099292A1 (ro) |
| CL (1) | CL2020002932A1 (ro) |
| CO (1) | CO2020015476A2 (ro) |
| CR (1) | CR20200602A (ro) |
| DK (1) | DK3790548T3 (ro) |
| EA (1) | EA202092720A1 (ro) |
| ES (1) | ES2964409T3 (ro) |
| FI (1) | FI3790548T3 (ro) |
| GE (1) | GEP20237527B (ro) |
| HR (1) | HRP20231447T1 (ro) |
| HU (1) | HUE064326T2 (ro) |
| LT (1) | LT3790548T (ro) |
| MA (1) | MA52569B1 (ro) |
| MD (1) | MD3790548T2 (ro) |
| MX (1) | MX2020012008A (ro) |
| PE (1) | PE20211211A1 (ro) |
| PH (1) | PH12020551898A1 (ro) |
| PL (1) | PL3790548T3 (ro) |
| PT (1) | PT3790548T (ro) |
| RS (1) | RS64922B1 (ro) |
| SG (1) | SG11202011102TA (ro) |
| SI (1) | SI3790548T1 (ro) |
| UA (1) | UA127229C2 (ro) |
| WO (1) | WO2019217924A1 (ro) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3790548T3 (fi) | 2018-05-11 | 2023-11-17 | Xenon Pharmaceuticals Inc | Menetelmiä jänniteriippuvaisen kaliumkanavan avaajan biosaatavuuden ja eksposition tehostamiseksi |
| TW202128627A (zh) | 2019-10-10 | 2021-08-01 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| KR20220113411A (ko) * | 2019-12-06 | 2022-08-12 | 제논 파마슈티칼스 인크. | KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도 |
| CA3207191A1 (en) * | 2021-02-09 | 2022-08-18 | Simon Neil PIMSTONE | Voltage-gated potassium channel opener for use in treating anhedonia |
| WO2022173853A1 (en) * | 2021-02-09 | 2022-08-18 | Xenon Pharmaceuticals Inc. | Conjoint therapy for treating seizure disorders |
| EP4074696A4 (en) * | 2021-10-27 | 2024-01-31 | Shanghai Zhimeng Biopharma Inc | POTASSIUM CHANNEL REGULATOR COMPOUND, PRODUCTION AND USE THEREOF |
| CN113698345B (zh) * | 2021-10-27 | 2022-02-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的化合物及其制备和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| WO2006130686A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors in combination with food |
| CA2650853A1 (en) | 2006-05-02 | 2007-11-15 | Chris Rundfeldt | Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms |
| US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| MX2009002002A (es) * | 2006-08-23 | 2009-07-22 | Valeant Pharmaceuticals Int | Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio. |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| FI3790548T3 (fi) | 2018-05-11 | 2023-11-17 | Xenon Pharmaceuticals Inc | Menetelmiä jänniteriippuvaisen kaliumkanavan avaajan biosaatavuuden ja eksposition tehostamiseksi |
-
2019
- 2019-05-10 FI FIEP19727216.4T patent/FI3790548T3/fi active
- 2019-05-10 KR KR1020207035334A patent/KR20210020892A/ko unknown
- 2019-05-10 DK DK19727216.4T patent/DK3790548T3/da active
- 2019-05-10 MX MX2020012008A patent/MX2020012008A/es unknown
- 2019-05-10 PT PT197272164T patent/PT3790548T/pt unknown
- 2019-05-10 JP JP2020562201A patent/JP2021523130A/ja active Pending
- 2019-05-10 EP EP23185386.2A patent/EP4279133A3/en active Pending
- 2019-05-10 ES ES19727216T patent/ES2964409T3/es active Active
- 2019-05-10 LT LTEPPCT/US2019/031872T patent/LT3790548T/lt unknown
- 2019-05-10 CN CN201980046273.0A patent/CN112384216A/zh active Pending
- 2019-05-10 CA CA3099292A patent/CA3099292A1/en active Pending
- 2019-05-10 HR HRP20231447TT patent/HRP20231447T1/hr unknown
- 2019-05-10 SI SI201930665T patent/SI3790548T1/sl unknown
- 2019-05-10 SG SG11202011102TA patent/SG11202011102TA/en unknown
- 2019-05-10 EP EP19727216.4A patent/EP3790548B1/en active Active
- 2019-05-10 AU AU2019265002A patent/AU2019265002A1/en active Pending
- 2019-05-10 RS RS20231089A patent/RS64922B1/sr unknown
- 2019-05-10 MD MDE20210233T patent/MD3790548T2/ro unknown
- 2019-05-10 HU HUE19727216A patent/HUE064326T2/hu unknown
- 2019-05-10 UA UAA202007781A patent/UA127229C2/uk unknown
- 2019-05-10 PL PL19727216.4T patent/PL3790548T3/pl unknown
- 2019-05-10 BR BR112020022713-7A patent/BR112020022713A2/pt unknown
- 2019-05-10 GE GEAP201915508A patent/GEP20237527B/en unknown
- 2019-05-10 PE PE2020001843A patent/PE20211211A1/es unknown
- 2019-05-10 EA EA202092720A patent/EA202092720A1/ru unknown
- 2019-05-10 WO PCT/US2019/031872 patent/WO2019217924A1/en active Application Filing
- 2019-05-10 CR CR20200602A patent/CR20200602A/es unknown
- 2019-05-10 MA MA52569A patent/MA52569B1/fr unknown
- 2019-05-13 US US16/410,851 patent/US11135214B2/en active Active
-
2020
- 2020-11-09 PH PH12020551898A patent/PH12020551898A1/en unknown
- 2020-11-11 CL CL2020002932A patent/CL2020002932A1/es unknown
- 2020-12-11 CO CONC2020/0015476A patent/CO2020015476A2/es unknown
-
2021
- 2021-10-01 US US17/449,785 patent/US20220062266A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3790548T2 (ro) | Metode de îmbunătățire a biodisponibilității și expunerii activatorului de canale de potasiu voltaj-dependente | |
| MX2023009611A (es) | Esteroides neuroactivos, y su metodo de uso. | |
| BR112019019193A2 (pt) | compostos de pirimidinil-piridilóxi-naftila e métodos para tratar de doenças e distúrbios relativos a ire-1 | |
| DE602006014694D1 (de) | Acyloxyalkylcarbamat-prodrugs von tranexansäure und anwendung | |
| MA35348B1 (fr) | 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk | |
| EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
| EA201690959A1 (ru) | Способ синтеза ингибитора индоламин-2,3-диоксигеназы | |
| BR0311494A (pt) | Novos indóis substituìdos | |
| EA199900669A1 (ru) | Промежуточные соединения для получения замещенных n-[аминоиминометил или аминометил)фенил]пропиламидов | |
| MA51669B1 (fr) | Modulateurs de tmem16a | |
| EA200602115A1 (ru) | Опиоидные соединения, замещенные карбоксамидогруппой | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BRPI0507120A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| BR112021021826A2 (pt) | Terapias de combinação compreendendo os inibidores de apremilast e tyk2 | |
| NO20050270L (no) | Nye forbindelser, deres anvendelse og fremstilling | |
| DK1284977T3 (da) | Thienodibenzoazulenforbindelser som tumornekrosefaktorhæmmere | |
| ZA202109193B (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| CO2022008001A2 (es) | Métodos para el tratamiento de trastornos depresivos | |
| CY1106225T1 (el) | Διαδικασια για την παρασκευη της 2-μεθυλ πιπepαζινης | |
| DK2155736T3 (da) | Ny carbamoyloxyarylalkanoylarylpiperazin- forbindelse, farmaceutiske sammensætninger, omfattende forbindelsen og fremgangsmåde til behandling af smerte, angst og depression ved indgivelse af forbindelsen | |
| MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). | |
| DE602004010314D1 (de) | Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren | |
| MX2021009170A (es) | Cristal de compuesto de diariltiohidantoina. | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine |